Phase II Study of Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Bladder cancer; Pelvic cancer; Urethral cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 04 Jan 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017.
- 04 Jan 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.